Aurora Cannabis Pivots to Medical as Consumer Sales Crater

The Edmonton-based company’s stock dropped 9% to $3.70 during midday trading, narrowly recovering from a fresh 52-week low of $3.68. The sell-off followed a fiscal third-quarter report that highlighted a deepening divide between Aurora’s struggling recreational business and its growth-oriented medical and propagation units. While total revenue rose to C$94.2 million, surpassing analyst expectations of C$92.4 million, the company swung to a net loss of C$1.7 million ($1.2 million), a sharp reversal from the C$28.1 million profit recorded during the same period last year.

A Strategic Retreat

In response to a 48% year-over-year decline in consumer cannabis revenue, Aurora announced it will exit select retail markets starting in the current fourth quarter. Management expects the move to streamline operations and generate significant cost savings, though it will likely result in lower adjusted sales in the near term. This contraction marks a decisive shift away from the hyper-competitive recreational sector, which has been plagued by oversupply and thin margins across the Canadian landscape.

The company is instead doubling down on its global medical cannabis business, which saw revenue climb 12% in the quarter ended Dec. 31. This segment remains a cornerstone of Aurora’s profitability strategy due to its superior margins and more stable regulatory environment. Additionally, the company’s plant propagation division emerged as a bright spot, posting 27% growth as it scales its agricultural infrastructure.